IMMUNO-ONCOLOGY ASSAYS MARKET ANALYSIS

Regional Analysis

To learn more about this report, request sample copy

North America remains the dominant region in the global immune-oncology assays market and is estimated to hold 39.1% of the market share in 2024 owing to the increase in prevalence/incidence of cancer and rising elderly population in the region, especially in the U.S. By harnessing the immune system, immuno-oncology aims to activate or augment the body's natural response to fight cancer. For instance, according to the American Cancer Society (ACS), in 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the U.S.

Asia Pacific is also expected to witness robust growth in the global immuno-oncology assays market due to the subsequent increase in the incidence of cancer and rise in geriatric population in the region. For instance, India’s cancer cases could increase by 12% in the next five years, with 1.5 million people projected to suffer from the non-communicable disease by 2025, up from 1.39 million in 2020, according to the report by the Indian Council of Medical Research (ICMR). This in turn is expected to increase the use of immuno-oncology assays.